TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00650806

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One matching placebo capsule orally once daily for 12 weeks.
Study: NCT01269346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Mesylate
Description: Eribulin mesylate 1.4 mg/m2 administered as an intravenous (IV) infusion (over 2 to 5 minutes) on Days 1 and 8 of each 3-week cycle.~Trastuzumab 8 mg/kg will be administered as in IV infusion over a 90-minute period on Day 1 of Cycle 1. Thereafter, trastuzumab 6 mg/kg will be administered as an IV infusion over a 30-minute period on Day 1 of each subsequent cycle.
Study: NCT01012609

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cetuximab in conjunction with external beam radiation therapy, followed by cetuximab and irinotecan
Description: External beam radiation therapy (5940 cGy in 180 cGy fractions) with weekly cetuximab (250 mg/m2/dose).4-8 weeks rest, 10 cycles of irinotecan (16 mg/m2/day x 5 consecutive days x 2 weeks) with weekly cetuximab (250 mg/m2/dose) at about 21 day intervals. Research biological evaluations will be performed in consenting patients as an optional portion of the study. Cetuximab is to be given every 7 days (+/- 2 days). Cetuximab does not need to be given on Day 1 of each week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cetuximab in conjunction with external beam radiation therapy, followed by cetuximab and irinotecan
Description: External beam radiation therapy (5940 cGy in 180 cGy fractions) with weekly cetuximab (250 mg/m2/dose).4-8 weeks rest, 10 cycles of irinotecan (16 mg/m2/day x 5 consecutive days x 2 weeks) with weekly cetuximab (250 mg/m2/dose) at about 21 day intervals. Research biological evaluations will be performed in consenting patients as an optional portion of the study. Cetuximab is to be given every 7 days (+/- 2 days). Cetuximab does not need to be given on Day 1 of each week.
Study: NCT01178268

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: XIENCE V EECSS
Description: Patients who will receive this stent.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CYPHER SELECT PLUS SECSS
Description: Patients who will receive this stent.
Study: NCT04640233

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gam-COVID-Vac
Description: Vaccine for intramuscular injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study: NCT05242393

Intervention type: OTHER
Intervention: No intervention is planned
Description: No intervention is planned

Intervention type: OTHER
Intervention: No intervention is planned
Description: No intervention is planned
Study: NCT02185066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20mg and Metformin XR 500mg (Reference)
Description: Group 1 receives Atorvastatin 20mg and Metformin XR 500mg first, then CJ-30056 second, with at 7-day wash-out period in between.~Group 2 receives CJ-30056 first, then Atorvastatin 20mg and Metformin XR 500mg second, with 7-day wash-out period in between.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20mg and Metformin XR 500mg (Reference)
Description: Group 1 receives Atorvastatin 20mg and Metformin XR 500mg first, then CJ-30056 second, with at 7-day wash-out period in between.~Group 2 receives CJ-30056 first, then Atorvastatin 20mg and Metformin XR 500mg second, with 7-day wash-out period in between.
Study: NCT03571100

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: Chlorhexidine administration prior to intravitreal injection (compared to gold standard povidine-iodine)
Study: NCT04249128

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Astaxanthin
Description: is a naturally-occurring carotenoid found in algae, shrimp, lobster, crab and salmon.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Astaxanthin
Description: is a naturally-occurring carotenoid found in algae, shrimp, lobster, crab and salmon.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Astaxanthin
Description: is a naturally-occurring carotenoid found in algae, shrimp, lobster, crab and salmon.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Astaxanthin
Description: is a naturally-occurring carotenoid found in algae, shrimp, lobster, crab and salmon.
Study: NCT04902495

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MTA Pro Root
Description: pulp therapy
Study: NCT02185066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-30056 20/500mg (Test)
Description: Group 1 receives Atorvastatin 20mg and Metformin XR 500mg first, then CJ-30056 second, with at 7-day wash-out period in between.~Group 2 receives CJ-30056 first, then Atorvastatin 20mg and Metformin XR 500mg second, with 7-day wash-out period in between.
Study: NCT04902495

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MTA HP Repair
Description: pulp therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biodentine
Description: pulp therapy
Study: NCT06141629

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: accu chek Aviva Expert
Description: This bolus calculator estimates the dose of insulin to be administrated on the basis of the following parameters: current blood glucose, grams of carbohydrate, carbohydrate to insulin ratio, insulin sensitivity, target blood glucose and quantity of insulin previously administered.
Study: NCT02237768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DIRITHROMYCIN 500 MG ENTERIC COATED TABLET

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DYNABAC 250 MG ENTERIC COATED TABLET
Study: NCT02469350

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Serious game
Description: Rehabilitation with serious game
Study: NCT01606969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: scalp infiltration solution
Description: Dex group: Dexmedetomidine 2mcg/ml-containing 1% lidocaine scalp injection by neurosurgeon(dosage: according to incision length)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: scalp infiltration solution
Description: 1:100000 epinephrine-containing 1% lidocaine scalp injection by neurosurgeon(dosage: according to incision length)
Study: NCT00752193

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic lactobacilli
Description: Probiotic lactobacilli in combination with antibiotic therapy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in combination with antibiotic therapy
Study: NCT00894140

Intervention type: DEVICE
Group type: OTHER
Intervention: DePuy Silent™ Hip femoral prosthesis
Description: A short cementless, femoral component for use in total hip arthroplasty
Study: NCT01436578

Intervention type: DRUG
Intervention: Posaconazole oral suspension 40 mg/mL
Description: Posaconazole oral suspension prescribed according to the current local label
Study: NCT00584012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovastatin
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV
Study: NCT01092286

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuromuscular warm-up
Description: neuromuscular warm-up exercises that take 20 minutes to perform
Study: NCT03571100

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Povidine-Iodine
Description: Povidine iodine administration prior to intravitreal injection (compared to chlorhexidine)
Study: NCT02950285

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baseline alert
Description: PCP notification at baseline that patient has atrial fibrillation, high stroke risk, and is not anticoagulated.
Study: NCT06141629

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: accu chek Aviva Expert
Description: This bolus calculator estimates the dose of insulin to be administrated on the basis of the following parameters: current blood glucose, grams of carbohydrate, carbohydrate to insulin ratio, insulin sensitivity, target blood glucose and quantity of insulin previously administered.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Accu Chek Aviva Nano
Description: This meter is a normal glucometer without bolus calculator.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Accu Chek Aviva Nano
Description: This meter is a normal glucometer without bolus calculator.
Study: NCT04567121

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Intensive intervention group
Description: Establish a team of chronic disease prevention managers (5 people), with each educator responsible for the intervention of 200 people. For sub-health population and chronic disease patients, there would be conducted health education interview twice, 4 calls, online communication 50 times once a year, controlling risk factors and making treatment plan.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: standard intervention group
Description: Conduct general health education without active management
Study: NCT02222168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: film-coated tablet
Study: NCT02584751

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Esophageal Motility
Description: Esophageal Motility will be used to measure a subject's ability to swallow a bolus (i.e. saline solution) and record pressure changes throughout the esophagus during the swallow. This will also be used to identify anatomical landmarks, such as lower esophageal sphincter, which are necessary for proper placement of 24hr pH catheter.
Study: NCT04452266

Intervention type: OTHER
Intervention: questionnaire assesment
Description: Each patient will to answer questions about their medical history.

Intervention type: OTHER
Intervention: questionnaire assesment
Description: Each patient will to answer questions about their medical history.
Study: NCT02222168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: film-coated tablet
Study: NCT00674440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-DOPA
Description: 0.08-0.16 mCi/kg once

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET scan
Study: NCT05665946

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample analysis
Description: Analysis of proposed biomarkers.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample analysis
Description: Analysis of proposed biomarkers.
Study: NCT05248854

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensorimotor exercise training
Description: The program included side stepping, tandem walking, perturbation exercise, overcoming mini obstacles, walking different surfaces and traditional hip and knee exercise. Participants applied these exercise as home program between postoperative second weeks and 8th weeks, 3-5 day /week , 20 25 min every session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core stabilization exercise training
Description: Core stabilization exercise program was also prepared parallel to the sensorimotor training group intensity; the program contained traditional hip and knee exercise combining the core stabilization as mat activities depending on previous research.core stabilization exercise program was also prepared parallel to the sensorimotor training group intensity; the program contained traditional hip and knee exercise combining the core stabilization as mat activities depending on previous research
Study: NCT04532827

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Case formulation with web-program
Description: The first meeting includes an interview to establish understanding on the participant´s symptomatology and current life situation, a case formulation (CF) will be build based on it. The CF is presented in the second session and modifications can be made to ensure acceptability for the participant. Goals for web program (WB) are set based on the CF and understanding of the factors contributing to the participant´s wellbeing.~WB modules are instructed to complete during the week. Modules include psychoeducation, experiential exercises and training aimed at improving wellbeing and psychological flexibility. Web-therapist will offer written feedback. The participants can contact the therapist via the WB and al messages will be replied within one week. Automatic reminders will be sent if a participant has not been active in the WB, the therapists will call participants who have discontinued using the WB.
Study: NCT01711424

Intervention type: DRUG
Intervention: OPTIVE PLUS®
Description: Patients with dry eye prescribed OPTIVE PLUS® in accordance with physician standard practice.
Study: NCT00885937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexpanthenol (Sinecort, BAY81-2996)
Description: 1 squeeze of Sinecort cream sufficient to cover the area of the application chamber, (=50 mikro liter)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Positive control, Na-laurylsulfat-solution
Description: 50 mikro liter of 0.5 % Sodium-laurylsulfate-solution

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Untreated skin under application chamber
Description: Application of treatment chamber as in arm 1 and arm 2 on untreated skin
Study: NCT00834366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol HCl
Description: Single oral administration in fasting conditions of 1x200mg Tramadol HCl 200 mg Film-coated Tablet or Tramadol HCl 200 mg Uncoated Tablets based on randomization schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol HCl
Description: Single oral administration in fasting conditions of 1x200mg Tramadol HCl 200 mg Film-coated Tablet or Tramadol HCl 200 mg Uncoated Tablets based on randomization schedule.
Study: NCT03839693

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin, Type A
Description: topical liniment

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin, Type A
Description: topical liniment

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle Formulation
Study: NCT01528839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Thyroxine
Description: L-Thyroxine as addon to ongoing stable antidepressant and /or mood stabilizing therapy: week 1: 100 mcg; week 2: 200 mcg: week 3 to week 6: 300 mcg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00552422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: domperidone
Description: 10mg orally four times per day
Study: NCT03696537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 30 mg/m2/day IV (total 5 doses) administered days -7 through -3 of conditioning regimen

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Marrow Irradiation (TMI)
Description: TMI will be delivered twice a day, at least 6 hours apart, on days -7 through -3 (total of 10 fractions) of conditioning regimen
Study: NCT00383929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Description: 32mg oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Description: 32mg oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Description: 32mg oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: 12.5 mg oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: 25 mg oral
Study: NCT04387201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyanocobalamin
Description: Cyanocobalamin (vitamin B12) 1000 mcg subcutaneous weekly for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyanocobalamin
Description: Cyanocobalamin (vitamin B12) 1000 mcg subcutaneous weekly for 6 weeks.
Study: NCT00965458

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alefacept
Description: Weekly intramuscular injections of alefacept (15 mg) for 2 cycles of 12 weeks each, separated by a 12 week pause in treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Weekly intramuscular injections of a placebo saline solution of equal volume to the alefacept group for 2 cycles of 12 weeks each, separated by a 12 week pause in treatment.
Study: NCT04491162

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Body weight support treadmill training + conventional therapy
Description: Conventional gait therapy was done based on the principles of the proprioceptive neuromuscular facilitation (PNF) and Motor Relearning program (MRP) concepts.~Patients in intervention arm were additionally trained with a 40% body weight support and a comfortable walking speed on treadmill for twenty minutes. The training, which was conducted three times a week, for period of two weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: Conventional gait therapy was done based on the principles of the proprioceptive neuromuscular facilitation (PNF) and Motor Relearning program (MRP) concepts.
Study: NCT01139138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab 6mg/kg IV every 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 200mg/m2 IV every 14 days
Study: NCT02583919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS-GCGRRx- Dose Level 1
Description: once weekly dosing for 26 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS-GCGRRx- Dose Level 2
Description: once weekly dosing for 26 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once weekly dosing for 26 weeks
Study: NCT00649506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin Macrocrystals 100 mg Capsules
Description: 100mg, single dose fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Macrodantin® 100 mg Capsules
Description: 100mg, single dose fed
Study: NCT01120106

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levosimendan
Description: patients enrolled in this group will receive a levosimendan continuous infusion at a rate of 0.1 mcg/kg/min

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: levosimendan
Description: patients enrolled in this group will receive a levosimendan continuous infusion at a rate of 0.1 mcg/kg/min
Study: NCT01139138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus daily po (dosage varies with cohort)
Study: NCT04885842

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: injection I-PRF
Description: injection I-PRF with brackets
Study: NCT02797951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Description: Administered SC
Study: NCT02569502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enfuvirtide
Description: Participants will receive a total daily dose of 180mg of enfurtide administered twice daily as a subcutaneous injection.
Study: NCT05473546

Intervention type: OTHER
Intervention: ARTIFICIAL NUTRITION
Description: ARTIFICIAL NUTRITION
Study: NCT00896545

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5-keys counseling
Description: 5-session small group intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling
Description: 5-session small group behavioral intervention
Study: NCT01120106

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: saline continuous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: saline continuous infusion
Study: NCT02378688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1303
Study: NCT00896545

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle counseling
Description: 5-session small group behavioral intervention
Study: NCT03264131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Brentuximab Vedotin will be given at 1.8 mg/kg IV over approximately 30 minutes on D1 every 21 days for 2-6 cycles. Responders (CR, PR or SD) who are not eligible for bone marrow transplant (BMT) and have CD30-positive ATLL will continue maintenance therapy with BV alone (1.8 mg/kg IV for approximately 30 minutes, every 21 days).
Study: NCT06540937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide Pill
Description: This is a single-arm, single-center, phase II clinical study. Primarily evaluated in advanced MEN-1 neuroendocrine tumors. The initial efficacy of leflunomide tablets in second-line treatment provided evidence for phase III clinical trials.
Study: NCT02716415

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calmoseptine Ointment
Description: A full structured skin care regimen is provided in a consistent fashion either by study personnel or by the participant's primary carer (family or ward staff) at each diaper change. Study nurse sub-investigator visit each participant twice per nursing shift (six times per day) either to deliver the care regimen or to observe that it is being delivered.~The regimen includes:~* regular diaper changing,~* gentle cleansing~* application of the trial ointment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Destin Maximum Strength 40% Zinc
Description: A full structured skin care regimen is provided in a consistent fashion either by study personnel or by the participant's primary carer (family or ward staff) at each diaper change. Study nurse sub-investigator visit each participant twice per nursing shift (six times per day) either to deliver the care regimen or to observe that it is being delivered.~The regimen includes:~* regular diaper changing,~* gentle cleansing~* application of the trial ointment
Study: NCT02151565

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HTEMS
Study: NCT02378688

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03264131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHEP
Description: Cyclophosphamide- 750 mg/m\^2 IV over approximately 1 hour on D1 every 21 days for 2-6 cycles~Doxorubicin- 50 mg/m\^2 IV over approximately 3-5 minutes on D1 every 21 days for 2-6 cycles.~Etoposide - 100 mg/m\^2 IV over approximately 1 hour each day for 3 days every 21 days for 2-6 cycles.~Prednisone - 100 mg, orally once daily for 5 days every 21 days for 2-6 cycles.
Study: NCT01762800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate/salmeterol 50/250mcg
Description: Active, 50/250mcg, Twice daily (morning and evening)
Study: NCT02151565

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Study: NCT02041325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Subjects will receive oral CC-5013 (lenalidomide) at 25 mg qd for 7 days prior to and 7 days after the vaccine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo for 7 days prior to and 7 days after the vaccine.